NASDAQ:IRD Opus Genetics Q4 2024 Earnings Results & Report $4.46 +0.05 (+1.13%) Closing price 04:00 PM EasternExtended Trading$4.45 -0.01 (-0.20%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Opus Genetics missed analyst expectations on both earnings and revenue in its Q4 2024 results, released March 31, 2025. The company reported EPS of -$1.27 versus the -$0.34 consensus estimate, while revenue of $3.40 million fell short of the $11.10 million estimate by $7.70 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 31, 2025TimeBefore Market OpensConference Call7:00 AM ET Opus Genetics EPS ResultsActual EPS-$1.27Consensus EPS -$0.34Beat/MissMissed by -$0.93One Year Ago EPSN/AEPS Beat Rate5 of last 7 quartersOpus Genetics Revenue ResultsActual Revenue$3.40 millionExpected Revenue$11.10 millionBeat/MissMissed by -$7.70 millionYoY Revenue GrowthN/AUpcoming EarningsOpus Genetics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Opus Genetics Q4 2024 Earnings FAQ Did Opus Genetics beat earnings estimates for Q4 2024? Opus Genetics (NASDAQ:IRD) reported earnings of -$1.27 per share for Q4 2024, missing the consensus estimate of -$0.34. The report was announced on Monday, March 31, 2025. What was Opus Genetics' revenue for Q4 2024? Opus Genetics reported revenue of $3.40 million for Q4 2024, against a consensus estimate of $11.10 million. When is Opus Genetics' next earnings date? Opus Genetics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Opus Genetics on the company's earnings history page. Opus Genetics Earnings HeadlinesCould an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?1 hour ago | insidermonkey.comCould an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?1 hour ago | uk.finance.yahoo.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.October 8 at 1:00 AM | Paradigm Press (Ad)JonesTrading Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) StockOctober 8 at 2:06 AM | americanbankingnews.comHead to Head Survey: Atara Biotherapeutics (NASDAQ:ATRA) versus Opus Genetics (NASDAQ:IRD)October 5 at 4:59 AM | americanbankingnews.comOpus Genetics (NASDAQ: IRD) director trims stake in $2.76 million saleOctober 5 at 1:02 AM | americanbankingnews.comSee More Opus Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email. Email Address About Opus GeneticsOpus Genetics (NASDAQ:IRD) is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms. Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function. Its programs are designed to deliver functional genetic material or otherwise correct disease-related biological processes in retinal cells. The company’s lead programs target selected forms of inherited retinitis pigmentosa and other rare retinal disorders. Founded in 2017, Opus Genetics is based in Durham, North Carolina, and conducts its development activities through collaborations with researchers, medical institutions, and clinical trial sites. As its therapies remain investigational, their safety and effectiveness have not been established for general use.View Opus Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
